APPLICATION
ANDA205182
TYPE
ANDA
ORIGINAL APPROVAL
2023-07-24
LATEST ACTION
2024-01-30
ROUTE
SUBCUTANEOUS
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription
Products
PLERIXAFORPrescription
PLERIXAFOR 24MG/1.2ML (20MG/ML) · SOLUTION · SUBCUTANEOUS
Approval history
2024-01-30Labeling · Supplement 1 · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.